IFNB1 and COVID-19: In this sense, it is possible that blocking type I interferon responses might be a strategy of SARS-CoV-2 to evade antiviral immune mechanisms, as we found very low induction of plasma IFN-α and IFN-β in both pandemic influenza A(H1N1) and COVID-19 patients.